Welcome to our dedicated page for WLII news (Ticker: WLII), a resource for investors and traders seeking the latest updates and insights on WLII stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect WLII's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of WLII's position in the market.
Willow Lane Acquisition Corp. II (Nasdaq: WLIIU / WLII) closed its initial public offering of 14,375,000 units at $10.00 per unit on Feb 17, 2026, including 1,875,000 units from the underwriters' overallotment option.
$143,750,000 of proceeds were placed in the company’s trust account. Each unit contains one Class A ordinary share and one-quarter of a redeemable warrant; each whole warrant converts to one share at $11.50 per share. Units began trading on Nasdaq on Feb 13, 2026 under WLIIU, with separate listings for shares and warrants expected as WLII and WLIIW. Management and advisors were named and an audited balance sheet will be filed on Form 8-K.